CR9434A - Derivados 39-desmetoxi de rapamicina - Google Patents

Derivados 39-desmetoxi de rapamicina

Info

Publication number
CR9434A
CR9434A CR9434A CR9434A CR9434A CR 9434 A CR9434 A CR 9434A CR 9434 A CR9434 A CR 9434A CR 9434 A CR9434 A CR 9434A CR 9434 A CR9434 A CR 9434A
Authority
CR
Costa Rica
Prior art keywords
derivatives
treatment
present
demetoxi
rapamycin
Prior art date
Application number
CR9434A
Other languages
English (en)
Inventor
Hendrik Beckmann Christoph
James Moss Steven
Mary Sheridan Rose
Zhang Mingqiang
Wilkinson Barrie
Original Assignee
Biotica Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotica Tech Ltd filed Critical Biotica Tech Ltd
Publication of CR9434A publication Critical patent/CR9434A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a derivados novedosos de 39-desmetoxirapamicina, metodos para su produccion, y usos de los mismos; en un aspecto adicional la presente invencion proporciona el uso de estos derivados de 39-desmetoxirapamicina en el tratamiento de cancer y/o malignidades de celulas B, la induccion o mantenimiento de inmunosupresion, el tratamiento de rechazo de transplantes, enfermedad injerto contra hospedero, trastornos autoinmunes, enfermedades de inflamacion, enfermedad vascular y enfermedades fibroticas, la estimulacion de regeneracion neuronal o el tratamiento de infecciones fungicas.
CR9434A 2005-03-11 2007-10-11 Derivados 39-desmetoxi de rapamicina CR9434A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0504994.5A GB0504994D0 (en) 2005-03-11 2005-03-11 Novel compounds

Publications (1)

Publication Number Publication Date
CR9434A true CR9434A (es) 2008-02-22

Family

ID=34508873

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9434A CR9434A (es) 2005-03-11 2007-10-11 Derivados 39-desmetoxi de rapamicina

Country Status (24)

Country Link
US (2) US7648996B2 (es)
EP (1) EP1856129B8 (es)
JP (1) JP5422788B2 (es)
KR (1) KR20070113282A (es)
CN (2) CN101175760B (es)
AU (1) AU2006221786B2 (es)
BR (1) BRPI0607441A2 (es)
CA (1) CA2600640C (es)
CR (1) CR9434A (es)
DK (1) DK1856129T3 (es)
ES (1) ES2527530T3 (es)
GB (1) GB0504994D0 (es)
HR (1) HRP20150012T1 (es)
IL (1) IL185688A0 (es)
MX (1) MX2007011131A (es)
NI (1) NI200700230A (es)
NO (1) NO20074594L (es)
NZ (1) NZ561607A (es)
PL (1) PL1856129T3 (es)
PT (1) PT1856129E (es)
RS (1) RS53778B1 (es)
RU (1) RU2391346C2 (es)
WO (1) WO2006095185A1 (es)
ZA (1) ZA200708601B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862538B1 (fr) * 2003-11-21 2006-03-03 Galderma Res & Dev Utilisation de l'idrocilamide pour la preparation d'une composition pharmaceutique pour le traitement de la rosacee
ZA200706804B (en) 2005-02-03 2008-10-29 Gen Hospital Corp Method for treating gefitinib resistant cancer
BRPI0608726A2 (pt) * 2005-03-11 2011-03-15 Biotica Tech Ltd uso de um análogo de 39-desmetoxirapamicina ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
AU2006221774A1 (en) * 2005-03-11 2006-09-14 Biotica Technology Limited Medical uses of 39-desmethoxyrapamycin and analogues thereof
AU2013204788B2 (en) * 2005-11-04 2016-12-08 Wyeth Llc Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
AU2016259316B2 (en) * 2005-11-04 2018-09-06 Wyeth Llc Antineoplastic combinations with mTOR inhibitor, herceptin, and/or HKI-272
KR101354828B1 (ko) * 2005-11-04 2014-02-18 와이어쓰 엘엘씨 ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합
AU2006315512B2 (en) 2005-11-14 2012-11-01 Ariad Pharmaceuticals, Inc. Administration of an mTOR inhibitor to treat patients with cancer
GB0609963D0 (en) 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
US20080249123A1 (en) * 2007-04-05 2008-10-09 Wyeth Wortmannin-rapamycin conjugate and uses thereof
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
US20080287675A1 (en) * 2007-05-18 2008-11-20 Abbott Laboratories Cascade system
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CA2725598C (en) 2008-06-17 2013-10-08 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
MX2011001318A (es) 2008-08-04 2011-03-04 Wyeth Llc Combinaciones antineoplasicas de 4-anilino-3-cianoquinolinas y capecitabina.
ES2645692T3 (es) 2008-11-11 2017-12-07 The Board Of Regents,The University Of Texas System Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
EP2416774B1 (en) 2009-04-06 2015-11-04 Wyeth LLC Treatment regimen utilizing neratinib for breast cancer
WO2011051960A2 (en) * 2009-09-25 2011-05-05 Cadila Healthcare Limited Process for the preparation of rapamycin derivatives
EP2762142A1 (en) 2009-10-30 2014-08-06 ARIAD Pharmaceuticals, Inc. Compositions for treating cancer
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US20170079962A1 (en) 2009-11-11 2017-03-23 Rapamycin Holdings, Llc Oral Rapamycin Preparation and Use for Stomatitus
EP2589383A1 (en) * 2011-11-06 2013-05-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin FKBP subtype-specific rapamycin analogue for use in treatment of diseases
GB201122305D0 (en) 2011-12-23 2012-02-01 Biotica Tech Ltd Novel compound
EP2906214A1 (en) 2012-10-12 2015-08-19 The Board of Regents of The University of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
EP2968281B1 (en) 2013-03-13 2020-08-05 The Board of Regents of The University of Texas System Mtor inhibitors for prevention of intestinal polyp growth
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CA2938626A1 (en) 2013-07-26 2015-01-29 John Rothman Compositions to improve the therapeutic benefit of bisantrene
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
DK3089737T3 (da) 2013-12-31 2021-12-13 Rapamycin Holdings Llc Orale rapamycin-nanopartikelpræparater og anvendelse.
CN113620978A (zh) 2014-09-11 2021-11-09 加利福尼亚大学董事会 mTORC1抑制剂
CN106153755B (zh) * 2015-04-24 2020-02-14 山东新时代药业有限公司 2-(叔丁基二甲基硅烷基氧基)乙醇的分析检测方法
WO2017040341A1 (en) * 2015-08-28 2017-03-09 Buck Institute For Research On Aging RAPAMYCIN ANALOGS SHOWING IMPROVED mTORC1 SPECIFICITY
JP2020507632A (ja) * 2017-02-10 2020-03-12 マウント タム セラピューティクス, インコーポレイテッドMount Tam Therapeutics, Inc. ラパマイシン類似体
EP3624863B1 (en) 2017-05-15 2021-04-14 C.R. Bard, Inc. Medical device with drug-eluting coating and intermediate layer
AR112834A1 (es) * 2017-09-26 2019-12-18 Novartis Ag Derivados de rapamicina
BR112020025283A2 (pt) 2018-06-15 2021-03-09 Navitor Pharmaceuticals, Inc. Análogos de rapamicina e usos dos mesmos
CN113226389B (zh) 2018-11-14 2022-11-08 乐通公司 在经改性设备表面上具有药物洗脱涂层的医疗设备
US20230063768A1 (en) 2019-02-07 2023-03-02 The Regents Of The University Of California Immunophilin binding agents and uses thereof
JP7487228B2 (ja) 2019-04-08 2024-05-20 バード・ペリフェラル・バスキュラー・インコーポレーテッド 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
CN110343639B (zh) * 2019-07-23 2021-04-27 中国医药集团总公司四川抗菌素工业研究所 一株产15(s)-o-乙基雷帕霉素的链霉菌
AU2020397938A1 (en) 2019-12-05 2022-06-23 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5023262A (en) 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5138051A (en) 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
WO1992021341A1 (en) 1991-05-31 1992-12-10 Pfizer Inc. Use of rapamycin prodrugs as immunosuppressant agents
US5708002A (en) * 1991-09-05 1998-01-13 Abbott Laboratories Macrocyclic immunomodulators
JP3140228B2 (ja) 1992-02-17 2001-03-05 ファイザー製薬株式会社 新規な大環状ラクトンおよびその生産菌
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
GB9315914D0 (en) * 1993-07-31 1993-09-15 Smithkline Beecham Plc Novel compound
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5385910A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
NZ277498A (en) 1993-12-17 1998-03-25 Novartis Ag Rapamycin derivatives
US5995457A (en) * 1993-12-22 1999-11-30 Jamail; Randall H. Method of masking data on digital video disks (DVD)
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
KR100400620B1 (ko) 1995-06-09 2004-02-18 노파르티스 아게 라파마이신유도체
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US6239124B1 (en) 1996-07-30 2001-05-29 Novartis Ag Pharmaceutical compositions for the treatment of transplant rejection or autoimmune or inflammatory conditions comprising cyclosporin A and 40-0-(2-hydroxyethyl)-rapamycin
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6485514B1 (en) * 1997-12-12 2002-11-26 Supergen, Inc. Local delivery of therapeutic agents
EP1200078A4 (en) 1999-07-09 2004-06-30 Univ Oregon Health & Science COMPOSITIONS AND METHODS ACTIVATING NERVOUS REGENERATION
PT1278758E (pt) 2000-04-27 2011-12-22 Univ Arizona Pró-fármacos de fosfato de combretastatina a-1 e fosfato de combretastatina b-1
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
EP3342411B1 (en) * 2001-02-19 2019-08-21 Novartis Pharma AG Rapamycin derivative for treating pancreas cancer
JP4547911B2 (ja) * 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
ES2544624T3 (es) * 2002-07-16 2015-09-02 Buck Institute For Research On Aging Producción de policétidos
US7160867B2 (en) 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
GB0417852D0 (en) 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products
AU2006221774A1 (en) 2005-03-11 2006-09-14 Biotica Technology Limited Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0504995D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Use of a compound

Also Published As

Publication number Publication date
US7648996B2 (en) 2010-01-19
US20100081682A1 (en) 2010-04-01
US20080188511A1 (en) 2008-08-07
KR20070113282A (ko) 2007-11-28
IL185688A0 (en) 2008-01-06
PL1856129T3 (pl) 2015-08-31
JP5422788B2 (ja) 2014-02-19
RU2391346C2 (ru) 2010-06-10
AU2006221786A1 (en) 2006-09-14
NO20074594L (no) 2007-10-15
PT1856129E (pt) 2015-01-16
EP1856129B1 (en) 2014-10-15
CA2600640A1 (en) 2006-09-14
RS53778B1 (sr) 2015-06-30
WO2006095185A1 (en) 2006-09-14
AU2006221786B2 (en) 2012-02-16
NZ561607A (en) 2011-01-28
US8008318B2 (en) 2011-08-30
ES2527530T3 (es) 2015-01-26
GB0504994D0 (en) 2005-04-20
MX2007011131A (es) 2007-11-13
EP1856129B8 (en) 2015-06-03
RU2007137668A (ru) 2009-04-20
EP1856129A1 (en) 2007-11-21
JP2008532991A (ja) 2008-08-21
BRPI0607441A2 (pt) 2010-04-06
CA2600640C (en) 2015-10-27
CN101175760A (zh) 2008-05-07
CN104211715A (zh) 2014-12-17
CN101175760B (zh) 2014-08-13
NI200700230A (es) 2008-05-13
ZA200708601B (en) 2009-02-25
HRP20150012T1 (xx) 2015-03-27
DK1856129T3 (en) 2015-01-05

Similar Documents

Publication Publication Date Title
CR9434A (es) Derivados 39-desmetoxi de rapamicina
ECSP077303A (es) 17-desmetilrapamicina y analogos de la misma, metodos para su produccion
UY31705A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
SI1827441T1 (sl) Kombinacije za zdravljenje bolezni, povezanih s celično proliferacijo
NO20075560L (no) Purin og imidazopyridin derivater for immunsuppresjon
CU24087B1 (es) Compuestos de carbazol
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
CR20120154A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CR20110477A (es) Inhibidores de enzimas de proteina cinasa activadas por mitogeno p38
MX2019004070A (es) Sistema de extraccion de un sistema de circuito cerrado.
TW200732347A (en) VEGF analogs and methods of use
NZ751284A (en) Novel jak1 selective inhibitors and uses thereof
TW200509892A (en) Novel aminobenzophenone compounds
TW200631583A (en) Substituted pteridines for the treatment of inflammatory diseases
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
CL2008003063A1 (es) Compuestos derivados de 1,3,4-tiadiazol espiro condensado, inhibidores de la actividad quinesina ksp; composicion farmaceutica; y su uso en el tratamiento de enfermedades proliferativas tales como el cancer, hiperplasia, hipertrofia cardiaca, enfermedades autoinmune, trastornos fungicos, artritis, rechazo a imjertos, entre otras.
ECSP13012824A (es) Derivados de (1,2,4)triazolo[4,3-a)quinoxalina como inhibidores de fosfodiesterasas
PA8650801A1 (es) Composiciones y formulaciones de ecteinascidina, como la ecteinascidina 743
ECSP10010196A (es) Derivados de amidas del ácido 6,7-dihidro-5h-imidazo[1,2-a]imidazol-3-carboxílico
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
ECSP11011483A (es) Piperidinas sustituidas
TW200635597A (en) Substituted pteridines for the treatment of inflammatory diseases
CU20110214A7 (es) Piperidinas sustituidas
TW200633711A (en) Substituted pteridines for the treatment of inflammatory diseases
AR076832A1 (es) Derivados de 1- amino-alquilciclohexano para el tratamiento de enfermedades inflamatorias de la piel

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)